BOSULIF vs TAGRISSO

Independent side-by-side comparison.

Rated against independent regulatory sources·Last updated August 23, 2026·How we rate

Possible drug interaction. BOSULIF and TAGRISSO are different prescription medicines. Combining or switching between them can cause interactions — talk to a pharmacist or prescriber before making changes. This page is not medical advice.

Attribute	BOSULIF	TAGRISSO
Rating	New	70/100
Pharmacy pays	—	—
Type	RX	RX
Active ingredient	BOSUTINIB MONOHYDRATE	OSIMERTINIB MESYLATE
Manufacturer	Pf Prism Cv	Astrazeneca
Dosage forms	Capsule, Tablet	Tablet
Drug class	Kinase Inhibitor	Kinase Inhibitor
Boxed warning	None	None
Treats	Bcr-Abl Positive Chronic Myelogenous Leukemia	Non-Small-Cell Lung Carcinoma

bosulif tagrisso

Rating

New

70/100

Pharmacy pays

—

Type

Active ingredient

BOSUTINIB MONOHYDRATE

OSIMERTINIB MESYLATE

Manufacturer

Pf Prism Cv

Astrazeneca

Dosage forms

Capsule, Tablet

Tablet

Drug class

Kinase Inhibitor

Boxed warning

None

Treats

Bcr-Abl Positive Chronic Myelogenous Leukemia

Non-Small-Cell Lung Carcinoma

Frequently asked questions

What is the difference between Bosulif and Tagrisso?

Bosulif contains Bosutinib Monohydrate, while Tagrisso contains Osimertinib Mesylate — they have different active ingredients.

Ratings are based on FDA regulatory (recall-safety) data. This comparison is for general reference only — not medical advice. Always consult a licensed professional before choosing or switching a medication.